title: Establishment of a cervical cancer model via inoculating SiHa Cells into humanized severe combined immunodeficient mice.
abstract: OBJECTIVE
  To establish a human papillomavirus (HPV) 16 positive cervical cancer model in the humanized severe combined immunodeficient (SCID) mouse.
  
  
  METHODS
  A HPV16 positive cervical carcinoma cell line (SiHa) was transplanted subcutaneously into SCID mice (SiHa-SCID); human peripheral blood lymphocyte (Hu-PBL) was transplanted intraperitoneally (Hu-PBL-SCID), Hu-PBL was transplated intraperitoneally and SiHa subcutaneously (Hu-PBL-SiHa-SCID), and, PBS was transplanted subcutaneously (PBS-SCID) as a control. The biological and immunological features were investigated.
  
  
  RESULTS
  The transplanted tumor grew slowly and no metastasis was found. The survival time of Hu-PBL-SiHa-SCID was significantly longer than that of SiHa-SCID. HPV16 DNA could be detected in all of the tumor tissues, but not in peripheral blood and organ tissues. Human serum IgG levels in Hu-PBL-SCID and Hu-PBL-SiHa-SCID were significantly elevated following immuno-reconstructed time elongating, and significantly higher in Hu-PBL-SiHa-SCID than those in Hu-PBL-SCID. The numbers of human CD3+, CD4+ and CD8+ T cells were significantly increased in the peripheral blood and spleen of Hu-PBL-SiHa-SCID and Hu-PBL-SCID mice, and significantly higher in Hu-PBL-SiHa-SCID than those of Hu-PBL-SCID mice. The weight of the spleen was significantly increased in Hu-PBL-SiHa-SCID. Tumor infiltrating lymphocytes (TILs) and human CD4+ T cells were detected in Hu-PBL-SiHa-SCID but not in SiHa-SCID mice. The spleen cells of Hu-PBL-SiHa-SCID mice displayed significantly stronger cytotoxicity to target cells than those of SiHa-SCID mice. No graft-versus-host disease (GVHD) was found in either Hu-PBL or Hu-PBL-SiHa-SCID mice.
  
  
  CONCLUSIONS
  A HPV16 positive cervical carcinoma model has been successfully established in SCID mice. This model can perfectly simulate the biological features of spontaneous human cervical cancer, and present anti-tumor immune response after the human immune system is reconstructed.
authors.affiliation: Central Laboratory, Women's Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
authors.forename: F
authors.initials: F
authors.lastname: Ye
authors.forename: H
authors.initials: H
authors.lastname: Chen
authors.forename: Z
authors.initials: Z
authors.lastname: Liang
authors.forename: W
authors.initials: W
authors.lastname: Lu
authors.forename: Q
authors.initials: Q
authors.lastname: Cheng
authors.forename: X
authors.initials: X
authors.lastname: Xie
mesh_terms: D000818:Animals; D002277:Carcinoma / Q000276:immunology / Q000473:pathology* / Q000821:virology; D045744:Cell Line, Tumor; D004195:Disease Models, Animal; D005260:Female; D052162:Human papillomavirus 16; D006801:Humans; D017710:Lymphocyte Transfusion; D051379:Mice; D016513:Mice, SCID; D009368:Neoplasm Transplantation / Q000379:methods / Q000473:pathology; D030361:Papillomavirus Infections; D014183:Transplantation, Heterologous; D002583:Uterine Cervical Neoplasms / Q000276:immunology / Q000473:pathology* / Q000821:virology